$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

$hcsg Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000073101217000082 Filed on July 28, 2017

Income Statement

Concept	2017 Q2	2016 Q2
Revenue	$470.9M	$386.6M
YoY Change	21.81%	8.78%
Cost Of Revenue	$407.3M	$332.2M
YoY Change	22.61%	9.2%
Gross Profit	$63.55M	$54.35M
YoY Change	16.95%	6.27%
Gross Profit Margin	13.5%	14.06%
Selling, General & Admin	$31.99M	$25.66M
YoY Change	24.65%	2.15%
% of Gross Profit	50.34%	47.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.300M	$1.300M
YoY Change	0.0%	17.22%
% of Gross Profit	2.05%	2.39%
Operating Expenses	$31.99M	$25.66M
YoY Change	24.65%	2.15%
Operating Profit	$31.56M	$28.68M
YoY Change	10.05%	10.25%
Interest Expense	$1.500M	$1.000M
YoY Change	50.0%	400.0%
% of Operating Profit	4.75%	3.49%
Other Income/Expense, Net
YoY Change
Pretax Income	$33.08M	$29.68M
YoY Change	11.44%	13.05%
Income Tax	$10.53M	$10.92M
% Of Pretax Income	31.82%	36.8%
Net Earnings	$22.55M	$18.76M
YoY Change	20.21%	15.18%
Net Earnings / Revenue	4.79%	4.85%
Basic Earnings Per Share	$0.31	$0.26
Diluted Earnings Per Share	$0.30	$0.26
COMMON SHARES
Basic Shares Outstanding	73.28M shares	72.57M shares
Diluted Shares Outstanding	74.27M shares	73.32M shares

Balance Sheet

Concept	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.10M	$100.6M
YoY Change	-23.36%	2.97%
Cash & Equivalents	$7.058M	$21.72M
Short-Term Investments	$70.10M	$78.90M
Other Short-Term Assets	$20.10M	$16.30M
YoY Change	23.31%	15.6%
Inventory	$40.60M	$37.60M
Prepaid Expenses	$20.05M	$16.28M
Receivables	$338.4M	$255.8M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$476.2M	$410.3M
YoY Change	16.06%	16.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.40M	$13.49M
YoY Change	-0.64%	5.48%
Goodwill	$50.47M	$44.44M
YoY Change	13.58%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.269M	$44.00K
YoY Change	2784.09%	10.0%
Total Long-Term Assets	$139.6M	$112.2M
YoY Change	24.33%	-16.53%
TOTAL ASSETS
Total Short-Term Assets	$476.2M	$410.3M
Total Long-Term Assets	$139.6M	$112.2M
Total Assets	$615.7M	$522.5M
YoY Change	17.84%	7.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$69.20M	$44.86M
YoY Change	54.26%	25.9%
Accrued Expenses	$49.10M	$54.80M
YoY Change	-10.4%	-17.84%
Deferred Revenue
YoY Change
Short-Term Debt	$16.20M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$146.9M	$108.9M
YoY Change	34.97%	-4.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$92.70M	$91.00M
YoY Change	1.87%	10.98%
Total Long-Term Liabilities	$92.70M	$91.00M
YoY Change	1.87%	10.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$146.9M	$108.9M
Total Long-Term Liabilities	$92.70M	$91.00M
Total Liabilities	$239.7M	$199.8M
YoY Change	19.97%	1.99%
SHAREHOLDERS EQUITY
Retained Earnings	$148.1M	$117.8M
YoY Change	25.73%	10.5%
Common Stock	$237.0M	$214.0M
YoY Change	10.77%	9.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.840M	$10.74M
YoY Change	-8.36%	-1.52%
Treasury Stock Shares	1.535M shares	1.698M shares
Shareholders Equity	$376.1M	$322.7M
YoY Change
Total Liabilities & Shareholders Equity	$615.7M	$522.5M
YoY Change	17.84%	7.36%

Cashflow Statement

Concept	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	$22.55M	$18.76M
YoY Change	20.21%	15.18%
Depreciation, Depletion And Amortization	$1.300M	$1.300M
YoY Change	0.0%	17.22%
Cash From Operating Activities	-$41.20M	$10.50M
YoY Change	-492.38%	-73.55%
INVESTING ACTIVITIES
Capital Expenditures	-$1.400M	-$1.500M
YoY Change	-6.67%	66.67%
Acquisitions
YoY Change
Other Investing Activities	-$3.700M	-$6.000M
YoY Change	-38.33%
Cash From Investing Activities	-$4.900M	-$7.500M
YoY Change	-34.67%	733.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.000M	-10.40M
YoY Change	-148.08%	-7.96%
NET CHANGE
Cash From Operating Activities	-41.20M	10.50M
Cash From Investing Activities	-4.900M	-7.500M
Cash From Financing Activities	5.000M	-10.40M
Net Change In Cash	-41.10M	-7.400M
YoY Change	455.41%	-126.91%
FREE CASH FLOW
Cash From Operating Activities	-$41.20M	$10.50M
Capital Expenditures	-$1.400M	-$1.500M
Free Cash Flow	-$39.80M	$12.00M
YoY Change	-431.67%	-70.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000731012
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73185000	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE SERVICES GROUP INC
CY2016Q4	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	financial_institution
CY2017Q2	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	financial_institution
	hcsg	Deferred Income Tax Expense Benefit Excluding Tax Benefit From Equity Compensation Plans DeferredIncomeTaxExpenseBenefitExcludingTaxBenefitFromEquityCompensationPlans	2541000	USD
	hcsg	Deferred Income Tax Expense Benefit Excluding Tax Benefit From Equity Compensation Plans DeferredIncomeTaxExpenseBenefitExcludingTaxBenefitFromEquityCompensationPlans	0	USD
	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	971000	USD
	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	-98000	USD
	hcsg	Line Of Credit Facility Number Of Financial Covenants LineOfCreditFacilityNumberOfFinancialCovenants	1	financial_covenant
	hcsg	Lineof Credit Facility Increase Decrease Remaining Borrowing Capacity LineofCreditFacilityIncreaseDecreaseRemainingBorrowingCapacity	-70700000	USD
	hcsg	Period Of Amortization Of Inventories And Supplies PeriodOfAmortizationOfInventoriesAndSupplies	P24M
	hcsg	Related Party Transaction Fees Paid Related Party As Percentage Of Overall Related Party Revenues RelatedPartyTransactionFeesPaidRelatedPartyAsPercentageOfOverallRelatedPartyRevenues	0.05
	hcsg	Related Party Transaction Fees Paid Related Party As Percentage Of Overall Related Party Revenues RelatedPartyTransactionFeesPaidRelatedPartyAsPercentageOfOverallRelatedPartyRevenues	0.05
	hcsg	Service Agreements Duration Of Service ServiceAgreementsDurationOfService	P1Y
	hcsg	Share Based Compensation Arrangement By Share Based Payment Award Maximum Term Of Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumTermOfGrants	P10Y
CY2016Q2	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	34.14
	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	34.14
CY2017Q2	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	39.38
	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	39.38
	hcsg	Stock Contingently Issuable Value Acquisitions StockContingentlyIssuableValueAcquisitions	3938000	USD
	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	82000	USD
	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	2304000	USD
CY2016Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	271276000	USD
CY2017Q2	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	338368000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	42912000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	69204000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	7686000	USD
CY2017Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	12471000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2091000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2873000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	236275000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2624000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20564000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21779000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-319000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	762000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	217664000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6911000	USD
CY2017Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7895000	USD
CY2016Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	USD
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	600000	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	500000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	500000	shares
CY2016Q4	us-gaap	Assets Assets	528446000	USD
CY2017Q2	us-gaap	Assets Assets	615746000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	414624000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	476183000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	178000	USD
CY2017Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1258000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	668000	USD
CY2017Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	86000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	68220000	USD
CY2017Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	68910000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	21651000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	22980000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	28671000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	18260000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	16435000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	27882000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	973000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	960000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67730000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	70082000	USD
CY2016Q2	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	181000	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	243000	USD
CY2017Q2	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-125000	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-173000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33189000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21719000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23853000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7058000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11470000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16795000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.36625
CY2017Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18875
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.37625
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3600000	shares
CY2017Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.18625
CY2017Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.18750
CY2016Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18375
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74204000	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74611000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72601000	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73076000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	742000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	746000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19338000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	38519000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	23153000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	45649000	USD
CY2016Q2	us-gaap	Cost Of Services CostOfServices	332211000	USD
	us-gaap	Cost Of Services CostOfServices	662255000	USD
CY2017Q2	us-gaap	Cost Of Services CostOfServices	407322000	USD
	us-gaap	Cost Of Services CostOfServices	752892000	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	24653000	USD
CY2017Q2	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	26657000	USD
CY2016Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	24119000	USD
CY2017Q2	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	26326000	USD
CY2016Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9822000	USD
CY2017Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9240000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	1300000	USD
	us-gaap	Depreciation Depreciation	2400000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	1300000	USD
	us-gaap	Depreciation Depreciation	2600000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3912000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4239000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	27374000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.52
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.61
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.51
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22303000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21784000	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	13700000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M12D
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	1107000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14672000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10651000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	9039000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4188000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2143000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3990000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3990000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3990000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3990000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14409000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31330000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	44438000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	50473000	USD
CY2016	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	29683000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	59287000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	33078000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	65357000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10923000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21901000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10527000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20789000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	43190000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	69187000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	7098000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	7343000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	1473000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	2504000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1295000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	238000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	552000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	5550000	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	9329000	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	1572000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4787000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6089000	USD
	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	4448000	USD
	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	2399000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	663000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	569000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	39.38
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	146935000	USD
CY2016Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1002000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1189000	USD
CY2016Q4	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2017Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1515000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3084000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	528446000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	615746000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	100871000	USD
CY2017Q2	us-gaap	Line Of Credit LineOfCredit	16182000	USD
CY2017Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	200000000	USD
CY2017Q2	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	129300000	USD
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y6M
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	67730000	USD
CY2017Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	70082000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20510000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3887000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11171000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6347000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20211000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6561000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	18760000	USD
	us-gaap	Net Income Loss NetIncomeLoss	37386000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	22551000	USD
	us-gaap	Net Income Loss NetIncomeLoss	44568000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	7531000	USD
CY2017Q2	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	7526000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	1286000	USD
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	963000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4397000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3319000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1269000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	600000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	600000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1133000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1081000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	578000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	600000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1133000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1100000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	602000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1081000	USD
CY2016Q4	us-gaap	Other Inventory OtherInventory	37800000	USD
CY2017Q2	us-gaap	Other Inventory OtherInventory	40621000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	26451000	USD
CY2017Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	13624000	USD
CY2017Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	13750000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	27374000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	27400000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2584000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	14628000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	15939000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2954000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2674000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13965000	USD
CY2017Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20054000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	57000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6284000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	334000	shares
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2501000	USD
	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	48000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	14681000	USD
CY2016Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	3100000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	5200000	USD
CY2017Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7000000	USD
	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	501000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	14500000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	127000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	169000	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	16182000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4777000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7257000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34019000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35178000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13455000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13399000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2150000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2100000	USD
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	153000	USD
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-118000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	120000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	120000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	130940000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	148134000	USD
CY2016Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	386556000	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	771363000	USD
CY2017Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	470876000	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	875366000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25664000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51010000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31991000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60201000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	984000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	315000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.020
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.019
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.260
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.251
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	700000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1305000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3900000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	61000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	33.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	544000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.52
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	53140000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2615000	shares
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2091000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2764000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.61
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7257000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.61
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.14
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	34338000	USD
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	10185000	USD
CY2017Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1535000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	338842000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	376077000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1603000	shares
CY2017Q2	us-gaap	Treasury Stock Value TreasuryStockValue	9840000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	748000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	699000	shares
CY2017Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	993000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	932000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73316000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73165000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74269000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74108000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72568000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72466000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73276000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73176000	shares
CY2016Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	23573000	USD
CY2017Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	23975000	USD
CY2016Q4	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	64080000	USD
CY2017Q2	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	66077000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial instruments that are subject to concentrations of credit risk are cash and cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. The Company’s marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, substantially all of the Company’s cash and cash equivalents and marketable securities were held in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> large financial institution located in the United States.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s clients are concentrated in the health care industry and are primarily providers of long-term care. The revenues of many of our clients are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could be made which could directly impact the governmental reimbursement programs in which the clients participate. As a result, the full effect of such programs may not be realized until these laws are fully implemented and governmental agencies issue applicable regulations or guidance. </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, valuations, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.</font></div></div>

Files In Submission

Name	View Source	Status
0000731012-17-000082-index-headers.html	Edgar Link	pending
0000731012-17-000082-index.html	Edgar Link	pending
0000731012-17-000082.txt	Edgar Link	pending
0000731012-17-000082-xbrl.zip	Edgar Link	pending
ceosection302certification.htm	Edgar Link	pending
cfosection302certification.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hcsg-20170630.xml	Edgar Link	completed
hcsg-20170630.xsd	Edgar Link	pending
hcsg-20170630_cal.xml	Edgar Link	unprocessable
hcsg-20170630_def.xml	Edgar Link	unprocessable
hcsg-20170630_lab.xml	Edgar Link	unprocessable
hcsg-20170630_pre.xml	Edgar Link	unprocessable
hcsg10qq22017.htm	Edgar Link	pending
locamendment2017july.htm	Edgar Link	pending
locamendment2017july001.jpg	Edgar Link	pending
locamendment2017july002.jpg	Edgar Link	pending
locamendment2017july003.jpg	Edgar Link	pending
locamendment2017july004.jpg	Edgar Link	pending
locamendment2017july005.jpg	Edgar Link	pending
locamendment2017july006.jpg	Edgar Link	pending
locamendment2017july007.jpg	Edgar Link	pending
locamendment2017july008.jpg	Edgar Link	pending
locamendment2017july009.jpg	Edgar Link	pending
locamendment2017july010.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
section906certificationq22.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

2017 Q2 Form 10-Q Financial Statement

#000073101217000082 Filed on July 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG HEALTHCARE SERVICES GROUP INC Stock $hcsg

2017 Q2 Form 10-Q Financial Statement

#000073101217000082 Filed on July 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg